Rallybio (NASDAQ: RLYB) — Perfil da empresa, notícias e dados financeiros
Rallybio is a biotech firm focused on developing therapies for severe rare diseases, advancing a diverse portfolio through clinical trials.
Rallybio
Rallybio (NASDAQ:RLYB) is a biotechnology firm dedicated to identifying and accelerating the development of transformative therapies for patients with severe and rare diseases. Rallybio's operations focus on advancing a diverse portfolio of promising therapeutic candidates through clinical trials, with the objective of addressing unmet medical needs in areas where treatment options are limited or non-existent. The company's projects range from preclinical discovery phases to advanced clinical trials, leveraging cutting-edge technologies and strategic collaborations to speed up the development process. Rallybio aims to improve the lives of patients by delivering innovative treatments that can offer significant health benefits and enhance quality of life.
Resumo
Operações
Produtos e/ou serviços de Rallybio
- Development of a treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare condition that affects platelet count in fetuses and newborns.
- Advanced therapies targeting rare diseases in immunology, hematology, and metabolic disorders, focusing on conditions with high unmet medical needs.
- Innovative biologics for the treatment of autoimmune diseases, leveraging new discoveries in immunotherapy to address challenging therapeutic areas.
- Research into novel treatments for complement-mediated disorders, exploring the potential of targeting the complement system in treating rare diseases.
- Drug development program aimed at rare forms of bone marrow failure, seeking to address the lack of effective treatments for these life-threatening conditions.
- Collaboration with academic and industrial partners to accelerate the development of therapies for rare diseases, utilizing cutting-edge technology and research methodologies.
equipe executiva do Rallybio
- Martin W. MacKayCo-Founder & Chairman
- Stephen UdenCo-Founder, President, CEO & Director
Últimas notícias sobre a Rallybio
Principais indicadores financeiros
Resultados divulgados pela Rallybio , em USD.
- Cap. de mercado
- 84,6 mi
- Receita (TTM)
- 646 mil
- P/L
- 3.5
- LPA (diluído, TTM)
- 4.6
- Dividend yield
- —
- Margem de lucro
- 7051.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 858 mil | -28,1 mi | -9 mi | |
| 636 mil | -60,5 mi | -57,8 mi | |
| 0 | -78,9 mi | -74,6 mi | |
| 0 | -67,9 mi | -66,7 mi |